Gapping up
News:
- VSTM +22.5% (Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-Free Survival Presented at ESMO 2021)
- SYBX +10% (reports Phase 2 data demonstrating reduction in plasma phenylalanine levels in patients with phenylketonuria)
- VXX +7.4% (trading higher with US futures down 1.5%)
- MRTX +7% (Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer; reports Phase 2 topline results for investigational Adagrasib in patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer)
- SPPI +5.3% (Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021)
- AZN +1.7% (IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer)
- MRNS +1.2% (FDA accepted for filing the company's New Drug Application for the use of ganaxolone in the treatment of seizures associated with CDKL5 deficiency disorder)
- CDXC +0.9% (reports new preclinical data shows positive effects of nicotinamide riboside in glaucoma, Alzheimer's disease, and cardiac ischemia-reperfusion injury mouse models)
Analyst comments:
- FCRD +2.5% (initiated with a Perform at Oppenheimer)